Terms ending in 2028
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,143,394 | PYRIDO(3,2-D)PYRIMIDINES Useful for Treating Viral Infections In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,637,531 | PYRIDO(3,2-D)PYRIDMIDINES Useful for Treating Viral Infections In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,017,591 | Substituted, Non-Coding Nucleic Acid Molecule for Therapeutic and Prophylactic Stimulation of the Immune System in Humans and Higher Animals In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,486,942 | Modulators of Pharmacokinetic Properties of Therapeutics In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 7,741,345 | Aza-Peptide Protease Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,324,244 | Process and Intermediates for Preparing Integrase Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,334,270 | Nucleoside Phosphoramidate Prodrugs In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 8,580,765 | Nucleoside Phosphoramidate Prodrugs In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 8,735,372 | Nucleoside Phosphoramidate Prodrugs In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 8,906,880 | Nucleoside Phosphoramidate Prodrugs In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| 23 more term ends in 2028 · Pro | |||||
10 of 33 patents shown. Soonest term end first, then patent number.
Pro members see all 33, including 16 expiring within the 18 months from Nov 17, 2026.
32 of these are in force and held by Gilead Sciences, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.